Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026986 (
myelodysplastic syndrome
)
14,926
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To clarify the role of
fragile histidine triad
(
FHIT
) in hematological malignancies, we examined the methylation status and the expression level of the
FHIT
gene in
myelodysplastic syndrome
(
MDS
) and acute myeloid leukemia (AML) cells in comparison with the methylation of the p15(INK4B) gene. The
FHIT
methylation was found in 13 of 94 (13.8%) AML and 22 of 40 (55.0%)
MDS
cases, but not in normal mononuclear cells (MNCs). Both the frequency and density of methylation increased in the advanced-stages
MDS
and the relapsed AML cases. Although
FHIT
and p15(INK4B) methylations were not correlated in
MDS
and AML, increased
FHIT
methylation at the relapse in AML was associated with p15(INK4B) methylation. The median expression level in AML was significantly higher than in normal MNCs, although the median expression level in those with methylation was significantly lower than in those without methylation. Furthermore, the methylation level at relapse was significantly higher than at diagnosis in AML. These results suggested that
FHIT
methylation was accumulated through the disease progression of
MDS
and AML, and the role of the
FHIT
gene as a tumor suppressor seemed different in AML and
MDS
.
...
PMID:Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. 1590 82
The
fragile histidine triad
(
FHIT
) gene plays an important role in anti-cancer and the abnormal methylation of
FHIT
gene is found in many carcinomas. The epigenetic changes of tumor suppressor genes (TSG) are now recognized as an abnormal mechanism contributing to the development of
myelodysplastic syndrome
(
MDS
). To clarify the role of
FHIT
in
MDS
, we examined the methylation status of
FHIT
in patients with
MDS
. Methylation-specific polymerase (MSP) chain reaction was performed to detect the aberrant promoter methylation of
FHIT
gene in 55 patients with
MDS
. The abnormal methylation of the
FHIT
gene was found in 26 of 55 (47.2%)
MDS
cases, but it was not in normal control. No relationship was found between
FHIT
gene methylation and sex, hematologic parameters, chromosomal abnormalities of
MDS
patients. However, the significant difference was observed in the frequencies of
FHIT
gene hypermethylation among patients with RA/RARS (7/25, 28.0%), RAEB (11/18, 61.1%) and RAEBt (8/11, 72.7%) (chi2 value=7.938, P=0.019). Furthermore, there was a positive correlation between the frequency of
FHIT
gene hypermethylation and different IPSS groups (chi2 value=10.110, P=0.018). The
MDS
patients with
FHIT
gene methylation had significantly shorter survival time than those without
FHIT
methylation (20.0 months vs. 40.0 months, P=0.025). These results suggested that aberrant methylation of the
FHIT
gene might be one of molecular events involved in the disease progression of
MDS
and be an adverse prognostic factor in
MDS
.
...
PMID:Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. 1836 46
